Gonadotrophin-releasing hormone antagonists for assisted conception
Authors:
- Hesham G Al-InanyHAHesham G Al-Inany
- Ahmed M Abou-SettaAAAhmed M Abou-Setta
- Mohamed AboulgharMAMohamed Aboulghar
- 19 July 2006
- reference entry
- Published by Wiley
- No. 3,p. CD001750
Abstract
Gonadotrophin‐releasing hormone antagonists produce immediate suppression of gonadotrophin secretion, hence, they can be given after starting gonadotrophin administration. This has resulted in dramatic reduction in the duration of treatment cycle. Two different regimes have been described. The multiple‐dose protocol involves the administration of 0.25 mg cetrorelix (or ganirelix) daily from day six to seven of stimulation, or when the leading follicle is 14 to15 mm, until human chorionic gonadotrophin (HCG) administration and the single‐dose protocol involves the single administration of 3 mg cetrorelix on day seven to eight of stimulation. Assuming comparable clinical outcome, these benefits would justify a change from the standard long protocol of GnRH agonists to the new GnRH antagonist regimens. To evaluate the evidence regarding the efficacy of gonadotrophin‐releasing hormone (GnRH) antagonists with the standard long protocol of GnRH agonists for controlled ovarian hyperstimulation in assisted conception. We searched Cochrane Menstrual Disorders and Subfertility Group's Specialised Register, MEDLINE and EMBASE databases from 1987 to February 2006, and handsearched bibliographies of relevant publications and reviews, and abstracts of scientific meetings. We also contacted manufacturers in the field. Randomized controlled studies comparing different protocols of GnRH antagonists with GnRH agonists in assisted conception cycles were included in this review. Two authors independently assessed trial quality and extracted data. If relevant data were missing or unclear, the authors have been consulted Twenty seven RCTs comparing the GnRH antagonist to the long protocol of GnRH agonist fulfilled the inclusion criteria. Clinical pregnancy rate was significantly lower in the antagonist group. (OR = 0.84, 95% CI = 0.72 to 0.97). The ongoing pregnancy/ live‐birth rate showed the same significant lower pregnancy in the antagonist group (P = 0.03; OR 0.82, 95% CI 0.69 to 0.98). However, there was statistically significant reduction in incidence of severe OHSS with antagonist protocol. The relative risk ratio was (P = 0.01; RR 0.61, 95% CI 0.42 to 0.89). In addition, interventions to prevent OHSS (e.g. coasting, cycle cancellation) were administered more frequently in the agonist group (P = 0.03; OR 0.44, 95% CI 0.21 to 0.93). GnRH antagonist protocol is a short and simple protocol with good clinical outcome with significant reduction in incidence of severe ovarian hyperstimulation syndrome and amount of gonadotrophins but the lower pregnancy rate compared to the GnRH agonist long protocol necessitates counseling subfertile couples before recommending change from GnRH agonist to antagonist.Keywords
This publication has 32 references indexed in Scilit:
- Comparison of the Luteal Phase after Pituitary Suppression With GnRH-Agonist Versus GnRH Antagonist in Controlled Ovarian HyperstimulationFertility and Sterility, 2005
- Comparison of GnRH Agonist and Antagonist Protocols Among Patients with Mild-Moderate Endometriosis and Endometrioma: A Novel Clinical ApproachFertility and Sterility, 2005
- A Prospective Randomized Study of Three Different Controlled Ovarian Hyperstimulation (COH) ProtocolsFertility and Sterility, 2005
- Impact of GnRH Agonist Versus GnRH Antagonist During Controlled Ovarian Hyperstimulation (COH) on Oocyte Maturity and Aneuploidy: A Pilot StudyFertility and Sterility, 2005
- Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administrationFertility and Sterility, 2005
- A prospective randomized study comparing gonadotropin-releasing hormone agonists or gonadotropin-releasing hormone antagonists in couples with unexplained infertility and/or mild oligozoospermiaFertility and Sterility, 2005
- A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilizationFertility and Sterility, 2005
- A modified gonadotropin-releasing hormone (GnRH) antagonist protocol failed to increase clinical pregnancy rates in comparison with the long GnRH protocolFertility and Sterility, 2004
- Comparison of daily ganirelix administration to a long protocol agonist for controlled ovarian hyperstimulation in oocyte donors: The results of a prospective randomized controlled trialFertility and Sterility, 2003
- Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulationFertility and Sterility, 2001